Discover our portfolio



Co-founded by Truffle, Symetis has developed new implant systems for transaortic valves.
The ACURATE valves are designed to treat patients suffering from severe and symptomatic aortic valve stenosis, who are considered at high risk for surgical valve replacement.
Instead of open-heart surgery, the replacement valve is delivered via a transcatheter percutaneous delivery system.
The ACURATE platform is recognized for its ease of use during valve implantation.

The company was sold in May 2017 to Boston Scientific for a total amount of $ 435M.

Contact Truffle Capital

14 + 3 =


5 Rue de la Baume, 75008 Paris, France
Tel: +33 1 82 28 46 00



Truffle Capital

Truffle Capital

5 Rue de la Baume, 75008 Paris, France
Tel: 01 82 28 46 00

© 2019 Truffle Capital



Truffle Capital 2019

Tous droits réservés
Mentions légales
Informations réglementaires



Réseaux sociaux